36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details
臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02810951 (ClinicalTrials.gov) | July 1, 2016 | 13/6/2016 | A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) | A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Epidermolysis Bullosa Dystrophica, Recessive | Genetic: FCX-007 | Castle Creek Biosciences, LLC. | NULL | Terminated | 7 Years | N/A | All | 6 | Phase 1/Phase 2 | United States |